MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1681/asn.0000000775

Медицинская библиотека · Journal of the American Society of Nephrology : JASN · 2025

Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality: Target Trial Emulation Studies.

Nie Sheng, Li Yanqin, Sun Yinfang, Chen Shan, Shao Xian, Pang Mingzhen, Zhou Shiyu, Su Licong, Chen Ruixuan, Luo Fan, Xu Xin, Hou Fan Fan, CRDS Study Investigators

СтатьяПеревод в очереди

Аннотация

KEY POINTS: It is uncertain whether the discontinuation of renin-angiotensin system (RAS) improves prognosis among patients during an episode of hospital-acquired AKI. Discontinuation of RAS inhibitors within 2 days after AKI was associated with lower risk of all-cause mortality as compared with continuation. Temporary discontinuation of RAS inhibitors during AKI episodes may improve outcomes in long-term users.

BACKGROUND

Renin-angiotensin system inhibitors (RASis) are widely used among patients with cardiovascular disease, diabetes, and CKD, which are high-risk populations for AKI. Evidence for the optimal management of RASi during an episode of AKI is lacking.

METHODS

We conducted a multidatabase cohort study using sequential target trial emulation framework from the China Renal Data System and Medical Information Mart for Intensive Care IV (MIMIC-IV) databases. Adult patients with hospital-acquired AKI who had been receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers treatment for at least 90 days were included. The primary outcomes were 30- and 180-day all-cause mortality. Adjusted cumulative incidences and risk differences were estimated using weighted pooled logistic regression models.

RESULTS

A total of 27,003 person-trials were identified from the China Renal Data System database (median [interquartile range] age, 70 [58–78] years; 12,972 [60%] male) and the MIMIC-IV database (median [interquartile range] age, 73 [63–82] years; 2825 [53%] male). The adjusted cumulative incidence of 30-day all-cause mortality was lower among person-trials with RASi discontinuation within 2 days after the hospital-acquired AKI than continuation (4.36% versus 5.91%), with a risk difference of −1.55% (95% confidence interval, −2.43% to −0.55%). Discontinuation of RASi was consistently associated with lower risk of all-cause mortality in the MIMIC-IV database, with similar beneficial associations observed across stratified analyses and multiple sensitivity analyses.

CONCLUSIONS

In this study, stopping RASi within the first 2 days of AKI detection was associated with a lower risk of all-cause mortality.

Для цитирования: Nie Sheng, Li Yanqin, Sun Yinfang, Chen Shan, Shao Xian, Pang Mingzhen, Zhou Shiyu, Su Licong, Chen Ruixuan, Luo Fan, Xu Xin, Hou Fan Fan, CRDS Study Investigators. Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality: Target Trial Emulation Studies.. Journal of the American Society of Nephrology : JASN. 2025. DOI: 10.1681/asn.0000000775.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.